ONC Insider Trading

Insider Ownership Percentage: 1.35%
Insider Buying (Last 12 Months): C$17,726.86
Insider Selling (Last 12 Months): C$0.00

Oncolytics Biotech Insider Trading History Chart

This chart shows the insider buying and selling history at Oncolytics Biotech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oncolytics Biotech Share Price & Price History

Current Price: C$1.78
Price Change: Price Decrease of -0.02 (-1.11%)
As of 03/21/2023 01:00 AM ET

This chart shows the closing price history over time for ONC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Oncolytics Biotech Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2022Allison HagermanSenior OfficerBuy4,200C$1.16C$4,851.004,200
6/14/2022Kirk LookSenior OfficerBuy6,000C$1.11C$6,656.4039,028
6/14/2022Matthew CoffeyDirectorBuy5,774C$1.08C$6,219.4688,433
6/7/2021Angela Frances HolthamDirectorBuy7,000C$3.59C$25,123.70108,336
8/28/2020Angela Frances HolthamDirectorBuy4,300C$2.35C$10,105.0076,518
3/27/2020Angela Frances HolthamDirectorBuy3,000C$2.03C$6,090.003,000
See Full Table

SEC Filings (Institutional Ownership Changes) for Oncolytics Biotech (TSE:ONC)

1.55% of Oncolytics Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Oncolytics Biotech logo
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Read More on Oncolytics Biotech

Today's Range

Now: C$1.78
Low: C$1.69
High: C$1.78

50 Day Range

MA: C$2.20
Low: C$1.73
High: C$2.53

52 Week Range

Now: C$1.78
Low: C$1.06
High: C$3.10


66,499 shs

Average Volume

49,082 shs

Market Capitalization

C$111.84 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Oncolytics Biotech?

Oncolytics Biotech's top insider shareholders include:
  1. Angela Frances Holtham (Director)
  2. Matthew Coffey (Director)
  3. Kirk Look (Senior Officer)
  4. Allison Hagerman (Senior Officer)
Learn More about top insider investors at Oncolytics Biotech.